Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Repligen Corp Raises FY 2013 Revenue Guidance; Reaffirms FY 2013 EBIT Guidance; Lowers FY 2013 Net Income Guidance


Thursday, 1 Aug 2013 07:30am EDT 

Repligen Corp announced that total revenue for fiscal 2013 is expected to be $65-$67 million, an increase from its prior guidance of $63-$65 million. This projection includes the receipt of royalties from Bristol-Myers Squibb on its U.S. sales of Orencia which the Company will no longer receive after December 31, 2013. Total operating income (EBIT) for fiscal 2013 is expected to be $20-$22 million, consistent with its prior guidance. Total net income for fiscal 2013 is expected to be $16-$18 million, a decrease from the Company's prior guidance of $18-$20 million, due primarily to a non-cash increase in tax expense. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $65 million and net income of $18 million for fiscal 2013. 

Company Quote

22.68
-0.32 -1.39%
25 Jul 2014